cycloserine has been researched along with HIV Coinfection in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 5 (83.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Centner, CM; Chirehwa, M; Court, R; de Vries, N; Denti, P; Gumbo, T; Harding, J; Maartens, G; McIlleron, H; Wiesner, L | 1 |
Jo, KW; Kim, WS; Lee, SD; Park, S; Shim, TS | 1 |
Court, R; de Vries, N; Gumbo, T; Harding, J; Maartens, G; McIlleron, H; Stewart, A; Wiesner, L | 1 |
Davis, JG; Farley, J; Lancaster, J; Odendaal, R; Shean, K; Van der Walt, M | 1 |
Horsburgh, CR; Kvasnovsky, C; Master, I; O'Donnell, MR; Padayatchi, N; Werner, L | 1 |
Adebola, SO; Adedeji, TO; Adefuye, BO; Oladeji, SM; Sogebi, OA | 1 |
6 other study(ies) available for cycloserine and HIV Coinfection
Article | Year |
---|---|
Neuropsychiatric toxicity and cycloserine concentrations during treatment for multidrug-resistant tuberculosis.
Topics: Adult; Antibiotics, Antitubercular; Cycloserine; Depression; Female; HIV Infections; Humans; Incidence; Isoxazoles; Male; Middle Aged; Oxazolidinones; Peripheral Nervous System Diseases; Prospective Studies; Psychoses, Substance-Induced; Risk Factors; Tuberculosis, Multidrug-Resistant | 2021 |
Treatment outcomes of rifampin-sparing treatment in patients with pulmonary tuberculosis with rifampin-mono-resistance or rifampin adverse events: A retrospective cohort analysis.
Topics: Adult; Age Distribution; Aged; Alcohol Drinking; Aminosalicylic Acid; Antitubercular Agents; Cohort Studies; Comorbidity; Cycloserine; Ethambutol; Female; Fluoroquinolones; HIV Infections; Humans; Isoniazid; Male; Middle Aged; Prothionamide; Pyrazinamide; Republic of Korea; Retrospective Studies; Rifampin; Severity of Illness Index; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2017 |
Steady state pharmacokinetics of cycloserine in patients on terizidone for multidrug-resistant tuberculosis.
Topics: Adult; Antitubercular Agents; Area Under Curve; Chromatography, Liquid; Cycloserine; Female; HIV Infections; Humans; Isoxazoles; Male; Middle Aged; Oxazolidinones; Prospective Studies; Regression Analysis; South Africa; Tandem Mass Spectrometry; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Serious treatment related adverse drug reactions amongst anti-retroviral naïve MDR-TB patients.
Topics: Adult; Antitubercular Agents; Coinfection; Cycloserine; Drug Resistance, Multiple, Bacterial; Female; Hearing Loss; HIV Infections; Humans; Isoxazoles; Male; Middle Aged; Mycobacterium tuberculosis; Ofloxacin; Oxazolidinones; Prospective Studies; Psychoses, Substance-Induced; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2013 |
Treatment outcomes for extensively drug-resistant tuberculosis and HIV co-infection.
Topics: Adolescent; Adult; Antitubercular Agents; Coinfection; Cycloserine; Drug Therapy, Combination; Ethambutol; Ethionamide; Extensively Drug-Resistant Tuberculosis; Female; HIV Infections; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Pyrazinamide; Retrospective Studies; Treatment Outcome; Tuberculosis, Pulmonary; Young Adult | 2013 |
Clinical predictors of aminoglycoside-induced ototoxicity in drug-resistant Tuberculosis patients on intensive therapy.
Topics: Adult; Age Factors; Aminoglycosides; Antitubercular Agents; Audiometry, Pure-Tone; Body Mass Index; Coinfection; Comorbidity; Cycloserine; Diabetes Mellitus; Female; Hearing Loss; HIV Infections; Humans; Kanamycin; Levofloxacin; Male; Middle Aged; Nigeria; Prospective Studies; Prothionamide; Pyrazinamide; Risk Factors; Time Factors; Tuberculosis, Multidrug-Resistant; Young Adult | 2017 |